Volume | 29,400,945 |
|
|||||
News | (1) | ||||||
Day High | 41.16 | Low High |
|||||
Day Low | 40.125 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Bristol Myers Squibb Co | BMY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
40.25 | 40.125 | 41.16 | 41.09 | 40.25 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
109,290 | 29,400,945 | US$ 40.71 | US$ 1,197,041,747 | - | 39.91 - 66.46 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:59:29 | 20 | US$ 41.15 | USD |
Bristol Myers Squibb (BMY) Options Flow Summary
Bristol Myers Squibb Co Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
83.09B | 2.02B | - | 45.01B | 8.03B | 3.97 | 10.35 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bristol Myers Squibb News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMY Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 41.54 | 41.675 | 39.91 | 40.57 | 16,171,800 | -0.3901 | -0.94% |
1 Month | 43.93 | 45.715 | 39.91 | 42.95 | 13,561,926 | -2.78 | -6.33% |
3 Months | 53.48 | 55.035 | 39.91 | 48.15 | 15,717,785 | -12.33 | -23.06% |
6 Months | 48.82 | 55.035 | 39.91 | 49.41 | 15,544,089 | -7.67 | -15.71% |
1 Year | 63.69 | 66.46 | 39.91 | 53.18 | 13,399,661 | -22.54 | -35.39% |
3 Years | 66.24 | 81.435 | 39.91 | 62.93 | 11,679,078 | -25.09 | -37.88% |
5 Years | 45.56 | 81.435 | 39.91 | 60.86 | 12,308,483 | -4.41 | -9.68% |
Bristol Myers Squibb Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |